The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.
May 24th 2024
James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.
Dr. Epperla on CAR T-Cell Therapy in MCL
November 15th 2017Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).
JCAR015 Experience Informs Future CAR-T Studies
The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.
Combinations Required to Further Advance Adoptive T-Cell Therapy
A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.
Personalized Medicine Moving to Forefront of Hematologic Malignancies
November 3rd 2017Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.
Novartis Submits sBLA for Tisagenlecleucel in Adults With Relapsed/Refractory DLBCL
Novartis has filed a supplemental biologics license application with the FDA to expand the indication for tisagenlecleucel (Kymriah) to include adults with relapsed/refractory DLBCL who are ineligible for ASCT.
Dr. Karmali Discusses Toxicites Associated With CAR T-Cell Therapies
October 20th 2017Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.
Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma
October 19th 2017Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.